• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Persistent and robust T-cell reactivity to the SARS-CoV-2 Omicron variant among immunized adults

byYuchen DaiandMichael Pratte
April 28, 2022
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Among adults vaccinated against SARS-CoV-2, there was a persistent and robust T-cell response despite mutations in the Omicron variant.

2. These findings suggest that cellular immunity against the Omicron BA.1 variant of SARS-CoV-2 from vaccination and/or previous infection was not compromised and will continue to protect against severe disease.

Evidence Rating Level: 2 (Good)

Study Rundown: With the emergence of highly contagious variants of SARS-CoV-2 such as Omicron, it is uncertain whether the cross-reactivity of the spike-specific T-cells among individuals who have had previous SARSCoV-2 infection or vaccinated against SARSCoV-2 will confer a broad enough adaptive immune response to respond. This study assessed the T-cell response to the mutated regions of the spike protein from the Omicron BA.1 variant among individuals vaccinated against COVID-19 and/or with immunity from previous COVID-19 infection. The main outcomes included the measurement of T-cell response to the mutated regions of the spike protein of the Omicron BA.1 variant and the assessment of residual T-cell immunity to the spike protein. Despite mutations in the Omicron variant of SARS-CoV-2, 80% of participants demonstrated adequate cellular immunity responses to the mutated regions of the spike protein. Furthermore, mutations as a result of the Omicron variant were associated with significantly reduced T-cell recognition compared to the vaccine strain. Lastly, the response to the entire spike protein was present in 100% of participants, while the proportion of remaining immunity to SARS-CoV-2 was approximately 87%. A limitation of this study was the reduced sample size in each cohort resulting in low statistical power for the identification of differences in T-cell responses between cohorts.

Click to read the study in JAMA Network Open

Relevant Reading: Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

In-Depth [prospective cohort]: This cohort study included 61 individuals (mean [range] age, 42 [21-62] years; 38 [62%] women) vaccinated from or infected with SARS-CoV-2 from a tertiary center in Rome, Italy during December 2021. Lymphocytes from blood samples were isolated and tested for reactivity to the SARS-CoV-2 spike protein. Overall, the median (range) frequency of CD4+ T cells reactivity to the mutated regions in the Omicron variant was 0.039% (0%-2.356%). Compared to the frequency of CD4+ cells reactive to the same regions of the ancestral strain (0.109% [0%-2.376%]), this was a 64% decrease. For CD8+ T cells, 0.02% (0%-0.689%) reacted to the mutated spike regions, compared to 0.039% (0%-3.57%) specific to the equivalent unmutated regions (49% reduction). Overall reactivity to the the full-length protein was maintained at approximately 87%.

RELATED REPORTS

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COVID-19T-cell
Previous Post

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

Next Post

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

May 16, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Next Post

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

Increased physical activity is a long-term protective factor for dementia

Shared decision-making tool for antidepressants improves patient and physician satisfaction

COVID-19 pandemic associated with worsening psychological distress across United Kingdom cohort studies

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.